Related Experiment Video
Updated: Feb 25, 2026

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
Published on: February 2, 2021
Plasma Exchange in ANCA-Associated Vasculitis With Kidney Involvement: Differential Outcomes by Kidney Function in a
Clara Escorcia-García1, Mauricio Restrepo-Escobar2, Lina Aguirre3
1Department of Internal Medicine, Division of Nephrology, University of Antioquia, Medellín, Colombia.
Insights
Plasma exchange (PLEX) did not reduce mortality or end-stage kidney disease (ESKD) in ANCA-associated vasculitis (AAV) overall. However, PLEX showed benefit for patients with severe kidney dysfunction (creatinine > 5.7 mg/dL).
Area of Science:
- Nephrology
- Rheumatology
- Immunology
Background:
- ANCA-associated vasculitis (AAV) commonly affects the kidneys, potentially leading to end-stage kidney disease (ESKD).
- The efficacy of plasma exchange (PLEX) in managing kidney involvement in AAV is not well-established.
Purpose of the Study:
- To evaluate the effectiveness of plasma exchange (PLEX) in patients with ANCA-associated vasculitis (AAV) and kidney dysfunction.
- To determine if PLEX impacts the composite outcome of all-cause mortality or ESKD in AAV patients with impaired kidney function.
Main Methods:
- Retrospective cohort study involving 163 patients with AAV and serum creatinine ≥ 1.5 mg/dL.
- Comparison of outcomes between patients who received PLEX and those who did not.
- Analysis of primary outcome (all-cause mortality or ESKD) and secondary outcomes, including in-hospital infections.
Main Results:
- Overall, PLEX was not associated with a significant reduction in the composite outcome of mortality or ESKD (aHR 1.04).
- In patients with baseline creatinine > 5.7 mg/dL, PLEX was linked to a lower risk of ESKD (aHR 0.38) and a borderline reduction in the composite outcome (HR 0.45, p=0.05).
- Patients receiving PLEX experienced a significantly higher rate of in-hospital infections (aRR 4.66, p=0.001).
Conclusions:
- Plasma exchange may not offer overall benefit for kidney outcomes in ANCA-associated vasculitis patients with moderate kidney dysfunction.
- PLEX could be beneficial for selected AAV patients with severe kidney impairment, warranting further investigation.
- Increased risk of in-hospital infections is a significant consideration when using PLEX in AAV patients.
Abstract:
ANCA-associated vasculitis (AAV) frequently involves the kidneys and may progress to end-stage kidney disease (ESKD). The benefit of plasma exchange (PLEX) in this setting remains uncertain. We conducted a retrospective cohort study of 163 patients with AAV and serum creatinine ≥ 1.5 mg/dL from two tertiary centers in Colombia, comparing PLEX versus no PLEX. The primary outcome was a composite of all-cause mortality or ESKD. Overall, PLEX was not associated with a reduction in the composite outcome (adjusted hazard ratio [HR] 1.04, 95% CI 0.61-1.76). Among patients with baseline creatinine > 5.7 mg/dL, PLEX was associated with a lower risk of ESKD (adjusted HR 0.38, 95% CI 0.14-0.97) and a borderline reduction in the composite outcome (HR 0.45, p = 0.05), with no benefit in those with lower creatinine levels. PLEX was associated with increased in-hospital infections (adjusted risk ratio 4.66, p = 0.001). These findings suggest a potential role for PLEX in selected patients with severe kidney dysfunction.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury I: Introduction
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury V: Interprofessional Care

